ARTICLE SUMMARY:
Now that Sensome has advanced its ultra-miniaturized in situ tissue characterization platform in stroke, it’s heading for the lung cancer market, where it has the potential to increase the diagnostic yield of bronchoscopic biopsies.
We’ve written before in these pages about Sensome and its pioneering microsensing technology for real-time, in situ tissue analysis, first, because of its Clotild clot-characterization technology, designed to help operators achieve the “first-pass effect” and improve outcomes after thrombectomy for stroke. (See “Ischemic Stroke: The First Pass Effect,” MedTech Strategist, September 19, 2019.) Because operators can choose among several thrombectomy approaches, having real-time insight into clot composition and length, and the potential difficulty or ease of clot removal, can meaningfully inform procedural decisions.
The Clotild stroke program is now well advanced. CEO and Sensome co-founder Franz Bozsak, PhD, reports that a manufacturing agreement with major guidewire maker Asahi Intecc positions the company for a European launch of the Clotild smart guidewire for ischemic stroke within three years. A second agreement granting Cosmotec exclusive rights in Japan for that indication will similarly support commercial entry in that market.
